AAAna Arizcorreta

Ana Arizcorreta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Arizcorreta has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality

    by Montserrat Montes de Oca Arjona, Mercedes Marquez, Maria Jose Soto, Claudio Rodriguez-Ramos, Alberto Terron, Antonio Vergara, Ana Arizcorreta, Clotilde Fernandez-Gutierrez, Jose Antonio Giron-González

    Objective: Analysis of the influence of portal hypertension on intestinal permeability in HIV-infected patients with hepatitis C virus (HCV)-related cirrhosis and of the prognostic significance of consequent macrophage activation. Methods: Twenty HIV-monoinfected patients, 70 patients with HIV-HCV coinfection, 20 of them with compensated and 50 with decompensated cirrhosis, and 20 healthy controls were evaluated for intestinal permeability [measured by lipopolysaccharide-binding protein (LBP) serum levels], macrophage activation [soluble CD14, soluble tumour necrosis factor receptor 55 Kd, and interleukin 6 (IL-6)], and activation of the rennin-angiotensin-aldosterone axis. Patients with decompensated cirrhosis were monitored for a median period of 429 days to analyze the prognostic factors implicated in survival. Results: Patients with decompensated cirrhosis show increased LBP levels compared with HIV-monoinfected patients. Patients with increased LBP concentration showed elevated soluble CD14, soluble tumour necrosis factor receptor 55 Kd, and IL-6 levels. Twenty-two patients died, from liver-related causes, during the follow-up, and 2 more underwent liver transplantation. Child-Pugh index, CD4 T-cell count, plasma aldosterone and serum IL-6 concentrations independently predicted liver-related mortality. Conclusions: Increased intestinal permeability, as measured by serum LBP levels, observed in patients with HIV infection is significantly higher in patients with decompensated liver cirrhosis. Proinflammatory cytokines (IL-6) are prognostic markers of HIV-HCV-coinfected patients with decompensated cirrhosis.


  • Sepsis fulminante y rabdomiólisis por Bacillus cereus en paciente con enfermedad de Hodgkin

    by Peña Gómez-Herruz, Juan José Gil-Fernández, Helga Guillen, Ana Arizcorreta


  • Role of Pegylated Interferon-α-2a and Ribavirin Concentrations in Sustained Viral Response in HCV/HIV-Coinfected Patients

    by Lf Lopez-Cortes, B Valera-Bestard, A Gutierrez-Valencia, R Ruiz-Valderas, L Jimenez, A Arizcorreta, A Terrón, P Viciana

    The effect of simultaneous plasma concentrations of pegylated interferon‐α‐2a (pegIFN‐α‐2a) and ribavirin (Rbv) on viral response has not been addressed to date. Hepatitis C virus (HCV)/human immunod...


  • Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients

    by José A Mira, Luis F López-Cortés, Dolores Merino, Ana Arizcorreta-Yarza, Antonio Rivero, Antonio Collado, María J Ríos-Villegas, Mercedes González-Serrano, Manuel Torres-Tortosa, Juan Macías, et al.

    Background: Haematological adverse events related to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy could affect the patients’ quality of life; however, the risk factors for severe haematological toxicity associated with this therapy in patients coinfected with hepatitis C virus (HCV) and HIV are unclear. The objective of this study was to identify predictors of severe haematological toxicity among HIV-HCV-coinfected patients treated with PEG-IFN plus RBV. Methods: This retrospective multicentric study included 237 HIV-HCV-coinfected patients on PEG-IFN plus RBV. Predictors of severe anaemia, neutropenia, thrombocytopenia and overall haematological toxicity were analyzed. Results: Eighty (34%) individuals showed an episode of severe haematological toxicity. Severe anaemia, neutropenia and thrombocytopenia occurred in 32 (13%), 42 (18%) and 26 (11%) patients, respectively. In the multivariate analysis, zidovudine use (adjusted odds ratio [AOR] 3.3; 95% confidence interval [CI] 1.6–10; P=0.001), baseline body weight 3 and platelet counts 3 were independent predictors of severe anaemia, neutropenia and thrombocytopenia, respectively. Conclusions: Zidovudine treatment, cirrhosis, baseline low body weight, use of PEG-IFN-α2a, and baseline haemoglobin level <14 g/dl are predictors of overall severe haematological toxicity secondary to PEG-IFN plus RBV in HIV-infected individuals. Low pretreatment levels of each haematological series predict a significant decrease of their values during therapy.


  • Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients

    by José A Mira, Bárbara Valera-Bestard, Ana Arizcorreta-Yarza, Mercedes González-Serrano, Julián Torre-Cisneros, Ignacio Santos, Salvador Vergara, Alicia Gutiérrez-Valencia, José A Girón-González, Juan Macías, et al.

    Introduction: The clinical applicability of early viral kinetics at week 4 in predicting sustained virological response (SVR) of pegylated interferon (peg-IFN) plus ribavirin (RBV) in HIV/HCV-coinfected patients is unclear. Our objective was to determine if rapid virological response (RVR) at week 4 of therapy with peg-IFN and RBV could predict SVR among HIV/HCV-coinfected patients. Methods: HIV/HCV-coinfected patients in whom an HCV viral load determination had been carried out at week 4 of therapy were included in the study. The positive predictive value (PPV) and the negative predictive value (NPV) of RVR (undetectable serum HCV RNA at 4 week) for SVR were calculated in the study population. Receiver operating characteristic curves were calculated to determine the best cutoff of HCV RNA decrease to predict treatment failure. Results: A total of 101 HIV/HCV-coinfected patients were included. RVR and SVR were observed in 39 (39%) and in 49 (48%) individuals, respectively. Of patients with RVR, 37/39 patients achieved SVR (PPV: 95%), whereas 50/62 individuals without RVR did not show SVR (NPV: 81%). The highest NPV (96%) was reached by using a cutoff level of HCV RNA decrease of 0.6 log 10 . By applying this cutoff level, treatment could have been discontinued in 25 (25%) patients. Conclusions: An undetectable serum HCV RNA determination at week 4 of treatment with peg-IFN plus RBV is a reliable predictor of SVR in HIV/HCV-coinfected patients. In addition, a decrease of HCV RNA less than 0.6 log 10 at this point of treatment could identify an appreciable proportion of individuals who will fail to achieve SVR.


  • Open Access

    What Length of Follow‐Up in Patients with HIV and Hepatitis C Virus Coinfection Is Necessary to Consider the Level of Transaminases to Be “Persistently Normal”?

    by P. Pérez‐Guerrero, M. J. Blanco, C. Martínez‐Sierra, A. Arizcorreta, J. A. Girón‐González

    To the Editor—An accelerated progression rate of liver fibrosis has been detected in patients with hepatitis C virus (HCV) infection who have elevated alanine a

  • Open Access

    T cell receptor excision circles (TRECs), CD4+, CD8+ and their CD45RO+ and CD45RA+ subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy

    by A. Arizcorreta, M. Márquez, C. Fernández-Gutiérrez, E. Pérez Guzmán, F. Brun, M. Rodríguez-Iglesias, J A Girón-González

    Interferon (IFN)-α induced CD4+ T lymphopenia is a toxic effect of the treatment of chronic hepatitis C virus (HCV) in human immunodeficiency virus (HIV)-co-infected patients. To increase the knowledge about this secondary effect, we performed an analysis of the evolution of the T cell receptor excision circles (TRECs), CD4+ and CD8+ T cells and of their CD45RO+ and CD45RA+ subpopulations during the treatment of chronic hepatitis HCV with peginterferon alpha (pegIFN-α) + ribavirin. Twenty HCV/HIV-co-infected patients, with undetectable HIV load after highly active antiretroviral therapy (HAART), were treated with pegIFN-α + ribavirin. TRECs were determined using real-time polymerase chain reaction. CD4+ and CD8+ T cells and their CD45RO+ and CD45RA+ subpopulations were analysed by two-colour flow cytometry. Median baseline CD4+ and CD8+ T cells were 592 mm3 and 874 mm3, respectively. Median baseline CD45RO+ subpopulation was 48% for CD4+ T and 57% for CD8+ T lymphocytes. A progressive decrease in both T cell populations, as well as of their CD45RO+ and CD45RA+ subpopulations, was detected, with a difference between the baseline and nadir levels approaching 50%. The evolution of T cell populations and TRECs was independent of the response to the treatment. T lymphocytes and their subpopulations returned to baseline levels at 24 weeks after the end of treatment, with the exception of the T CD4+ CD45RA+ subpopulation. The ratio of CD4+ CD45RO+/CD4+ CD45RA+ increased from 0·89 (baseline) to 1·44 (24 weeks after the end of the therapy). TRECs/ml did not return to the basal values. In conclusion, a significant reduction of CD4+ and CD8+ T cells, and of their CD45RA+ and CD45RO+ subpopulations, in HIV/HCV co-infected patients treated with pegIFN-α was observed. Both subpopulations increased after the suppression of treatment, but the CD4+ CD45RA subpopulation did not reach the basal levels as a consequence, at least in part, of a decrease in thymic production.


  • Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease

    by Nicolás Merchante, José A Girón-González, Mercedes González-Serrano, Julian Torre-Cisneros, José A García-García, Ana Arizcorreta, Josefa Ruiz-Morales, Pilar Cano-Lliteras, Fernando Lozano, Carmen Martínez-Sierra, et al.

    To find the survival and the predictors of death of HIV-infected patients with hepatitis C virus (HCV)-related end-stage liver disease (ESLD). A prospective cohort study set in the infectious diseases units of four tertiary care public hospitals in Andalucía, Spain. From a multicentric cohort of 2664 HIV/HCV-co-infected patients, all consecutive patients with HCV-related cirrhosis who presented with the first hepatic decompensation from January 1997 to June 2004 were followed-up and 153 patients were included. The survival and the demographic, HIV-related and liver-related factors associated with death were evaluated. Ninety-five (62%) patients died during the follow-up. In 79 (85%) individuals, the cause of death was liver related. The median survival time was 13 months. Independent predictors of survival were Child score [hazard ratio (HR), 1.2; 95% confidence interval (CI), 1.08–1.37; P = 0.001], CD4+ cell count at decompensation lower than 100 cells/μl (HR, 2.48; 95% CI, 1.52–4.06; P < 0.001) and hepatic encephalopathy as the first hepatic decompensation (HR, 2.45; 95% CI, 1.41–4.27; P = 0.001). HAART was prescribed to 101 (66%) patients. The cumulative probability of survival in patients under HAART was 60% at 1 year and 40% at 3 years, versus 38 and 18%, respectively, in patients not treated with HAART (P < 0.0001). The HR (95% CI) of death in patients on HAART was 0.5 (0.3–0.9), (P = 0.03). The survival of HIV/HCV-co-infected patients with ESLD is extremely poor. Immunosuppression and markers of severe liver disease predict liver-related mortality in these patients. HAART seems to be associated with a reduced liver-related mortality.


  • Open Access

    Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus–Infected Patients with Chronic Hepatitis C: A European Collaborative Study

    by Luz Martin‐Carbonero, Yves Benhamou, Massimo Puoti, Juan Berenguer, Jose Mallolas, Carmen Quereda, Ana Arizcorreta, Antonio Gonzalez, Jurgen Rockstroh, Victor Asensi, et al.

    A study was performed in 10 European health care centers in which 914 patients coinfected with hepatitis C virus (HCV) and human immunodeficiency vir